Herborium Group, Inc. Focuses on a Lucrative Botanical Therapeutics Market
May 28 2010 - 4:00PM
Marketwired
Herborium Group, Inc. (PINKSHEETS: HBRM) (www.herborium.com), a
botanical therapeutics® company that develops, licenses and markets
all natural, herbal medicinal products, has focused its efforts on
developing aggressive routes of taping into $33 billion over the
counter alternative medicine market in the USA and over a trillion
USD global market for alternative and complementary medicine.
The Company business model focuses on emerging market
opportunities spearheaded by the growth of a new market sector
located between high-cost, high-risk, ethical pharmaceuticals and
commoditized classic nutraceuticals (supplements). The Company uses
clinical validation and a proactive regulatory strategy based on
the FDA Guidance for Industry: Botanical Drug Products (FDA
Guidance 2004) to establish and maintain a differential
advantage.
Herborium pipeline of botanical therapeutics in the sectors of
dermatology (Acne -- global market is over 55 Billion USD and over
60 million Americans are diagnosed and affected yearly by different
forms of acne -- www.acnease.com), women's and men's health,
including BPH (benign prostate hyperplasia affects over half of
male population at the age of 50+) and liver health, belong to the
most growing category of CAM products (self care costs) that
reached $22 Billion in the US last year with majority going to
purchase of non-vitamin, and non-mineral products.
"With the conversion of such factors as health economics,
directing consumers to spend money on prevention and on non ethical
products (lower insurance coverage) and to pharmaceutical companies
being forced to remove drugs from the market for safety reasons (La
Roche and Accutane for acne or Vioxx for pain), Herborium is
ideally positioned to take advantage of those emerging market
opportunities," said Dr. Agnes P. Olszewski, President of Herborium
Group. "During last four months we have focused our activities on
preparing to penetrate new markets with our existing products
including targeting of foreign markets. We have signed or are in
final stage of negotiating new distribution agreements in the USA
and abroad that will greatly increase our customer base. We expect
that our bottom line will significantly benefit from those
initiatives in 2010 and 2011," continues Dr. Olszewski.
"We are also planning to introduce new and complementary
products. We are especially excited about expected product line
extension in the field of dermatology with a product targeting
acne," adds Dr. Olszewski
"While securing additional resources we plan to address needs of
consumers and health providers that look for highly efficient,
proven safe and effective all natural alternatives in treatment and
prevention of number of health problems and concerns," concludes
Dr. Olszewski
About Herborium Group, Inc. Herborium
Group, Inc., a botanical therapeutics® company, focuses on
developing, licensing, and marketing proprietary, botanical based
medicinal products to consumers and healthcare professionals. The
Company business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses clinical
validation and a proactive regulatory strategy based on the FDA
Guidance for Industry: Botanical Drug Products (FDA Guidance 2004)
to establish and maintain a differential advantage. Herborium
harvests its therapeutic candidates from Traditional Chinese
Medicine and utilizes Western regulatory, clinical and marketing
strategies to successfully introduce the products to the Western
markets. The company secured a pipeline of botanical ingredients
based products in the areas of dermatological needs, Prostate
Health (BPH), Liver Diseases, Women's Health and selected sexual
disorders resulting from cardiovascular disease, use of
anti-depressants, surgical procedures, and other problems.
Herborium Group sells its products in the United States, the United
Kingdom, and continental Europe through a network of distributors,
specialty retailers, and e-commerce.
Certain matters discussed in this press release are
"forward-looking statements" intended to qualify for the safe
harbors from liability established by the Private Securities
Litigation Reform Act of 1995. In particular, the Company's
statements regarding trends in the marketplace and potential future
results are examples of such forward-looking statements. The
forward-looking statements include risks and uncertainties,
including, but not limited to, the consummation and the successful
integration of current and proposed acquisitions, the timing of
projects due to the variability in size, scope and duration of
projects, estimates and guidance made by management with respect to
the Company's financial results, backlog, critical accounting
policies, regulatory delays, clinical study results which lead to
reductions or cancellations of projects, and other factors,
including general economic conditions and regulatory developments,
not within the Company's control. The factors discussed herein and
expressed from time to time in the Company's filings with the
Securities and Exchange Commission could cause actual results and
developments to be materially different from those expressed in or
implied by such statements. The forward-looking statements are made
only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstance. You should
review the Company's filings, especially risk factors contained in
the Form 10-K and the forms 10-Q.
Company Contact: Dr. Agnes P. Olszewski President &
CEO Tel: (201) 647.3757
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jul 2023 to Jul 2024